Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature. 2006 Aug 16; [Epub ahead of print]
The worldwide spread of H5N1 avian influenza has raised concerns that this virus might acquire the ability to pass readily among humans and cause a pandemic. Two anti-influenza drugs currently being used to treat infected patients are oseltamivir (Tamiflu) and zanamivir (Relenza), both of which target the neuraminidase enzyme of the virus. Reports of the emergence of drug resistance make the development of new anti-influenza molecules a priority. Neuraminidases from influenza type A viruses form two genetically distinct groups: group-1 contains the N1 neuraminidase of the H5N1 avian virus and group-2 contains the N2 and N9 enzymes used for the structure-based design of current drugs. Here we show by X-ray crystallography that these two groups are structurally distinct. Group-1 neuraminidases contain a cavity adjacent to their active sites that closes on ligand binding. Our analysis suggests that it may be possible to exploit the size and location of the group-1 cavity to develop new anti-influenza drugs.
See Also:
Latest articles in those days:
- [preprint]A systematic review of laboratory investigations into the pathogenesis of avian influenza viruses in wild avifauna of North America 13 hours ago
- [preprint]Seabird and sea duck mortalities were lower during the second breeding season in eastern Canada following the introduction of Highly Pathogenic Avian Influenza A H5Nx viruses 13 hours ago
- [preprint]Novel introductions of human-origin H3N2 Influenza viruses in Swine, Chile 13 hours ago
- Long term evolution of human seasonal influenza virus A(H3N2) is associated with an increase in polymerase complex activity 13 hours ago
- Humoral correlates of protection against influenza A H3N2 virus infection 13 hours ago
[Go Top] [Close Window]